author-photo

Nicoletta Testoni

University of Bologna

426

Papers

7732

Citations

Citation Trend

Filter By

Papers (426) Sort By

Journal Conference Others

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway.

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (1)
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.

2021 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (1)
Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Author response for "Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant"

2021
Show All
- Source
- Cite
- Save
Citations (0)
An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma.

2020 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (1)
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.

2020 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (11)